DATATRAK Provides Unique Advantages to a Clinical Trial Sponsor With a Project in Russia

DATATRAK Provides Unique Advantages to a Clinical Trial Sponsor With a Project in Russia

Multilingual capabilities allow trainers to conduct meeting in Russian language and Internet structure in this country gives sponsors pricing advantages for using DATATRAK

CLEVELAND, Dec. 7 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (NASDAQ:DATA), the leading and most experienced Application Service Provider ("ASP") in the Electronic Data Capture ("EDC") industry today announced that its training department recently held an investigator meeting in Russian for one of its clients. The investigator meeting involved more than 50 new users which included investigators, site coordinators and clinical research associates from an international contract research organization. This investigator meeting was held in St. Petersburg, Russia as part of a large multinational clinical trial where DATATRAK EDC(R) is being used for data collection and review at all locations.

During this meeting it was learned that Internet Service Providers (ISPs) in Russia often charge their customers based upon the amount of data transmitted. Under this business model, DATATRAK's delivery platform that utilizes the widely-adopted Citrix(R) architecture would be economically advantageous to the clinical trial sponsors and/or research sites since only small packets of the actual entries into a field are transmitted. With some other web-based applications, the entire page and therefore larger informational content is sent with each transmission.

DATATRAK made the decision to implement its global solution using Citrix(R) so that a rich and highly-performing Internet experience could be delivered to users around the world independent of bandwidth. This decision has been extremely effective at creating DATATRAK's reputation for the fastest performing EDC architecture, especially at low connection speeds that are often seen at many locations in global studies. DATATRAK has never had to require the installation of high-speed lines anywhere in the world in order to satisfactorily deliver its EDC product to investigative sites. When using DATATRAK EDC(R) only the information that has changed is actually transmitted. Just the answers are sent, not the questions. This architecture also has inherent security advantages and in this content-dependent business model utilized by some Russian ISPs, it would also lead to reduced Internet costs compared to web-based platforms.

"The extensive multilingual capability that resides within our company has been of tremendous value and this is just one more example of our ability to satisfy customer demands anywhere in the world," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "One would think that extensive multilingual capabilities on a help desk are commonplace, but our experience even with multibillion dollar companies is that the provision of up to nine different languages with someone knowledgeable about clinical trials and technology is challenging and expensive. Our efforts in the multilingual area endear users to our Solutions Center. Ms. Ninel Dadon, MA, a Senior User Support Specialist in our Solutions Center located in Bonn, Germany provided the EDC training in the native language of the investigators. Our delivery platform now has four important advantages when conducting clinical trials with EDC, which are: fast system performance leading to a high user satisfaction, the absence of a requirement for high-speed lines at sites which is necessary with other products, audit trail tracking on a field level basis and reduced costs for data transmission with some ISP business models."

About DATATRAK International

DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(R) and related services to the pharmaceutical, biotechnology, and medical device industries. DATATRAK EDC(R) was developed in order to deliver clinical research data from investigative sites to clinical trial sponsors faster and more efficiently than conventional, manual methods. DATATRAK EDC(R) can be deployed worldwide in either a distributed platform using laptop computers or in a centralized environment using the Internet. DATATRAK EDC(R) software and its earlier versions have successfully supported many international clinical studies involving thousands of clinical research sites and encompassing tens of thousands of patients in over 40 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 14 separate drugs that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bonn, Germany. Its common stock is listed on the Nasdaq Stock Market under the symbol "DATA." Visit the DATATRAK International, Inc. web site at http://www.datatrak.net/ or http://www.datatraknet.de/ .

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. Factors that may cause actual results to differ materially from those in the forward- looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market the DATATRAK EDC(TM) software; the development and fluctuations in the market for EDC technology; continued unreliability of the Internet infrastructure; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; dependence on key personnel; governmental regulation; the early stage of the Company's EDC business and operations; and general economic conditions. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry.


Source: DATATRAK International, Inc.

CONTACT: Jeffrey A. Green, Pharm.D., FCP, President and Chief Executive
Officer, +1-440-443-0082 x112, or Terry C. Black, Chief Financial Officer,
+1-440-443-0082 x110, both of DATATRAK International, Inc.; or Neal Feagans,
Investor Relations of Feagans Consulting, Inc., +1-303-449-1184

Web site: http://www.datatraknet.com/
http://www.datatraknet.de/


-------
Profile: intent